AD_____

Award Number: W81XWH-18-1-042

TITLE: Rare Variants in Systemic Sclerosis (SSc, Scleroderma)

PRINCIPAL INVESTIGATOR: Maureen D. Mayes, MD, MPH

CONTRACTING ORGANIZATION: University of Texas Health Science Center

Houston, Texas 77030-5400

REPORT DATE: September 2019

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

♦ Approved for public release; distribution unlimited

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
Sept 2019	Annual	15 Aug 2018 - 14 Aug 2019

4. TITLE AND SUBTITLE

Rare Variants in Systemic Sclerosis (SSc, Scleroderma)

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-18-1-0423

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Maureen D. Mayes, MD, MPH

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Texas Health Science Center

Houston, Texas 77030-5400

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

The subject/topic area of this research is Systemic Sclerosis (SSc, Scleroderma). The purpose of the research is to identify genetic variants that contribute to SSc disease susceptibility and influence outcome. The approach involves whole genome sequencing of 100 trios (300 individuals including affected case and both parents). Previous Genome-Wide-Association-Studies (GWAS) have identified gene regions that are associated with disease but the majority of these are in non-coding areas so the impact of these variants is unclear. This study will identify rare variants (both inherited and de novo mutations) and will analyze these mutations according to the role they likely plan in disease pathogenesis. The immediate outcome of this project will be identification of the causal variants in multiple pathways associated with SSc susceptibility with the long-range impact will be the identification of the role these variants plan in disease causation and severity/outcome.

15. SUBJECT TERMS-

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU		19b. TELEPHONE NUMBER *(include area code)*

Table of Contents

"Rare Variants in Systemic Sclerosis (SSc, Scleroderma)

Page

1. **INTRODUCTION:** The subject/topic area of this research is Systemic Sclerosis (SSc, Scleroderma). The purpose of the research is to identify genetic variants that contribute to SSc disease susceptibility and influence outcome. The approach involves whole genome sequencing of 100 trios (300 individuals including affected case and both parents). Previous Genome-Wide-Association-Studies (GWAS) have identified gene regions that are associated with disease but the majority of these are in non-coding areas so the impact of these variants is unclear. This study will identify rare variants (both inherited and de novo mutations) and will analyze these mutations according to the role they likely plan in disease pathogenesis. The immediate outcome of this project will be identification of the causal variants in multiple pathways associated with SSc susceptibility with the long-range impact will be the identification of the role these variants plan in disease causation and severity/outcome.
2. **KEYWORDS:** Systemic Sclerosis, Scleroderma, Whole Genome Sequencing (WGS), genetic variants, rare variants.
3. **OVERALL PROJECT SUMMARY:** This study is on track for completion of the largest whole genome sequencing (WGS) project in scleroderma. The samples have been submitted for sequencing and quality control procedures have been done requiring the replacement of DNA from 2 individuals. Data are eagerly anticipate in this coming year along with analysis and genotype/phenotype correlations.
4. **ACCOMPLISHMENTS:**
    - **What were the major goals of the project?**
        - Task 1: Institutional Review Board (IRB) and DOD Human Research Protection Office (HRPO) approval. Timeline months 1-6 (15 Aug 2018 – 14 Jan 2019); actually HRPO approval was received later than expected on 11 Jul 2019 due to a miscommunication– but this has been resolved..
            - UT Houston IRB approval was obtained previously under the general approval for the genetics studies in SSc; a notice was sent to the IRB and accepted as a defined sub-study with the most recent annual reviews up-to-date as of 22 Jan 2019; so **completed**.
            - (Note Baylor College of Medicine – BCM - IRB approval is handled by the Collaborating Investigator, Dr. Brendan Lee, in his report); **completed**.
            - HRPO approval was received 11 Jul 2019 (HRPO Log Number E00551.1a) so **completed**.
        - Task 2: Prioritization, preparation and distribution of samples to be sent to BCM for genotyping: Timeline months 7- 8 (15 Feb 2019 – 14 Apr 2019)
            - Samples were identified on the basis of protocol-defined criteria and prepared for shipping during this time and were subsequently sent to BCM. So **completed.**
        - Task 3: Sequencing of 300 samples with appropriate quality control measures: Timeline months 9-18 (15 Apr 2019 – 14 Feb 2020)
            - All samples were sent to BCM for whole genome sequencing; of the samples sent 2 failed quality control measures and new replacement aliquots were prepared and sent to BCM on 19 Aug 2019. So **underway and on schedule.**

- Task 4: Processing, including imputation using the generated sequence data. Timeline months 19-21 (15 Feb 2020 – 14 May 2020). **Awaiting data** from Task 3.
- Task 5: Data analysis and prioritization of candidates for validation in other, future cohorts. Timeline months 22-36 (15 May 2020 – 14 Aug 2021). **Awaiting data** from Task 4.
- Task 6: Association analysis of the most likely identified variants with clinical disease features. Timeline months 34-36 (15 May 2021 – 14 Aug 2012). **Awaiting da**ta from Tasks 3 and 4.
- Task 7: Preparation of manuscripts for publication. Timeline months 34-36 (15 May 2021– 14 Aug 2021). **Awaiting data** from Task 6.
- Task 8: Quarterly meetings between the UT-H and BCM teams to coordinate all aspects of the project and review and interpret data as it becomes available. Timeline months 3-36 (15 Nov 2019 – 14 Aug 2021). **Ongoing.**
    - We have had 2 face-to-face meetings and 2 conference calls involving both teams for a total of 4 meetings since the study started. We are up-to-date on these and plan to continue to meet on a regular basis – at least quarterly or more frequently as the data become available.

- **What was accomplished under these goals?**
    - Tasks 1 and 2 have been completed and Task 3 is well underway with sequencing data expected to be complete on-time or even ahead of schedule. The analysis and interpretation phases are expected to be quite time-consuming so generating the sequence data ahead of schedule will be welcome. Task 8 (quarterly meetings of the UT-H and BCM teams) is ongoing as scheduled.
- **What opportunities for training and professional development has the project provided?**
    - Nothing to report**.**
- **How were the results disseminated to communities of interest?**
    - Nothing to report.
- **What do you plan to do during the next reporting period to accomplish the goals?**
    - We fully anticipate that the sequence data will have been generated by the next annual report (end of second year = 14 Aug 2020) and analysis well underway (Tasks 3 and 4 anticipated completion 14 May 2020).
    - Additionally, Task 5 evaluation in other cohorts should be initiated.

5. **IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*
    - **What was the impact on the development of the principal discipline(s) of the project?**
        - Nothing to Report.

        - Nothing to Report at this time.
    - **What was the impact on other disciplines?**
        - Nothing to Report.
    - **What was the impact on technology transfer?**
        - Nothing to Report.
    - **What was the impact on society beyond science and technology?**
        - Nothing to Report.
6. **CHANGES/PROBLEMS:** *The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*
    - **Changes in approach and reasons for change**
        - There have been no changes in approach.
    - **Actual or anticipated problems or delays and actions or plans to resolve them**
        - There was a delay in HRPO approval due to a miscommunication, but this was resolved and the project was able to move forward in a timely fashion.
    - **Changes that had a significant impact on expenditures**
        - There were no changes that had a significant impact on expenditures.
    - **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**
        - None
    - **Significant changes in use or care of human subjects - None**
    - **Significant changes in use or care of vertebrate animals. None**
    - **Significant changes in use of biohazards and/or select agents None**
7. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*
    - **Publications, conference papers, and presentations**
        - **Journal publications.** None to date.
        - **Books or other non-periodical, one-time publications.** None to date.
        - **Other publications, conference papers, and presentations.** None to date.
    - **Website(s) or other Internet site(s)**
      None to date.
    - **Technologies or techniques**
      None to date.

- **Inventions, patent applications, and/or licenses**
  None to date.
- **Other Products**
  None to date.

8. **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**
   - **What individuals have worked on the project?**
     - *Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change."*

Name:	Maureen D. Mayes, MD, MPH (No change from submission)
Project Role:	Principal Investigator; Initiating PI
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Dr. Mayes is responsible for the overall conduct of the study and for the timely completion of all aspects (Tasks 1 through 8); she supervises UT project personnel and organizes the weekly UT meetings, the quarterly UT-BCM meetings to review progress, potential problems, data collection and results.
Funding Support:	**New:** GSK: A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and explore efficacy of GSK2330811 in subjects with diffuse cutaneous systemic sclerosis. Galapagos: Orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis Eicos: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Intravenous Iloprost in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis University of Michigan: Long-term follow-up of Participants of the Phase II study to evaluate subcutaneous abatacept v. placebo in diffuse cutaneous systemic sclerosis-a double-blind, placebo-controlled, randomized trial (ASSET)

Name:	Dianna Milewicz, MD
Project Role:	Co-Investigator
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	0.6 calendar months
Contribution to Project:	Dr. Milewicz has a strong background in the genetic basis of vascular diseases. Her role to date is that she has provided guidance on study design thus far and in the upcoming years she will advise on the analysis and interpretation of the genetic data. She has served as an advisor on Dr. Mayes' previous scleroderma genetic studies and has worked with the Baylor College of Medicine Genetics group on multiple projects
Funding Support:	**New:** NIH/NHLBI: Novel genetic Insight into the molecular pathogenesis of atherosclerosis. NIH: Medical Scientist Training Program Texas Heart Institute: Fibromuscular Dysplasia Project Marfan Foundation: Asprosin's Role in Suppressed Appetite and Progeroid Appearance of Marfan Lipodystrophy Syndrome and Neonatal Marfan Syndrome Patients American Heart Association: Molecular Pathogenesis of Occlusive Cerebrovascular Disease Resulting from ACTA2 Mutations

Name:	Claudia Pedroza, PhD (no change from submission)
Project Role:	Co-Investigator, statistician
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	0.6 calendar months
Contribution to Project:	Dr. Pedroza has been involved in the planning and implementation of the project to date to ensure that data will be interpreted in light of available clinical outcomes.
Funding Support:	No changes

Name:	Patricia Gonzales, LVN (no change from submission)
Project Role:	Project Coordinator
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.6 calendar months
Contribution to Project:	Ms Gonzales is responsible for the day-to-day operations of the study, overseeing database queries and reporting to the investigators regarding progress, time lines and review of expenditures.
Funding Support:	

Name:	Julio Charles (no change from submission)
Project Role:	Laboratory Manager
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Mr Charles is responsible for overseeing the selection, aliquoting and distribution of samples for genotyping and sequencing studies. He coordinates delivery to the Baylor research lab; he attends the weekly lab meetings as well as the project-specific quarterly meetings between the UT and Baylor research groups.
Funding Support:	

Name:	Hau Pham (no change from submission)
Project Role:	Research Assistant
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Ms. Pham is responsible for the day-to-day work in the Rheumatology Research Lab, to implement sample selection, DNA quantification, DNA measurement and record keeping of samples distributed to Baylor as well as DNA extraction on new samples as needed, and autoantibody determination on these new samples.
Funding Support:	

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**
    - Ms. Jun Ying, Genetics Data Supervisor at 1.8 calendar months, has left the University as of 6/30/2019 and her position was replaced by Ms. Marka Lyons on 8/16/19.
- **What other organizations were involved as partners?**
    - Note: Dr. Brendan Lee at Baylor College of Medicine was included in the original application as Collaborating/Partnering PI. and no changes have been made to this relationship; he continues as Collaborating/Partnering PI. As collaborating PI he will submit his own annual report.

9. **SPECIAL REPORTING REQUIREMENTS**
    - **COLLABORATIVE AWARDS:** The Collaborating PI (Dr. Brendan Lee, Baylor College of Medicine) will submit a separate report as required.
    - **QUAD CHARTS:** The Quad chart will be attached and uploaded on the website.
10. **APPENDICES:** Not applicable.

Rare Variants in Systemic Sclerosis (SSc, Scleroderma)

Log# PR170866 Grant
W81XWH-18-1-0423

PI: Maureen D. Mayes **Org:** University of Texas Health Science Center **Award Amount:** 924,285.00

Study/Product Aim(s)

The overall goal is to identify rare variants that increase susceptibility to SSc & influence clinical outcomes. Specific aims:
1) to identify genetic variants by whole genome sequencing (WGS) on 100 trios (300 individuals) with predicted functional consequences; to identify variants that are preferentially transmitted to cases; to identify *de novo* variants.
2) To replicate the top candidates from Aim 1 above, by targeted genotyping of additional samples (3500 cases and 1,000 controls).

Approach

This application is a collaboration between the University of Texas and the Baylor Human Genome Sequencing Center on already collected DNA samples from trios with clinical and serological characterization. Detailed genotyping strategies and analysis are included in the original proposal.

UT-HOUSTON and BAYLOR COLLEGE OF MEDICINE: COLLABORATIVE PROJECT TO IDENTIFY RARE VARIANTS IN SYSTEMIC SCLEROSIS

Accomplishment: Place a description of the latest scientific accomplishment here. Limit the comments to three lines or less to make them fit; be succinct. These comments are valuable since they show progress.

Timeline and Cost

Activities CY	18	19	20	21
Tasks 1, 2 & 3a completed				
Task 3-b: QC procedures				
Task 4 – sequencing to be done				
Tasks 5 – 7 to be done; 8 ongoing				
Estimated Budget ($K)	$89,861	$308,095	$308,095	$218,234

Updated: University of Tx Health Science Center, 30 Aug 2019

Goals/Milestones (Project funded/start date = 15 Aug 2018)
CY18 – 19 Goals –Task 1.a. IRB approval at UT-Houston and Baylor College of Medicine (BCM) completed; Task 1.b. DOD HRPO approval completed. (Timeline Task 1: months 1-6)
Task 2: Prioritization, preparation and distribution of samples to BCM for genotyping – completed (Timeline Task 2: months 7-8)
Task 3.a**.** Quality control measures on samples – completed
Task 3.b. Replacement of 2 samples that failed above QC measures; 2 failed sample replacements sent to BCM 8/19/2019 (Timeline Task 3: months 9-18 months)
Task 4. Sequencing of samples (Timeline Task 4: months 19-21)
This is ongoing and should be completed by end of month 21
No change in timelines – Tasks 5 -7 should be on schedule.
Task 8: UTH & BCM team mtgs have been held quarterly..
Budget Expenditure to Date
Actual Expenditure to Date: $239,389

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
14/09/2019	Annual	15 Aug 2018 – 14 Aug 2019

4. TITLE AND SUBTITLE
Rare Variants in Systemic Sclerosis (SSc, Scleroderma)

5a. CONTRACT NUMBER
W81XWH1810423

5b. GRANT NUMBER
PR170866

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Maureen D. Mayes, MD, MPH

E-Mail: Maureen.d.mayes@uth.tmc.edu

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Texas Health Science Center
UT Health
7000 Fannin St
Houston, Texas 77030-5400

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT: The subject/topic area of this research is Systemic Sclerosis (SSc, Scleroderma). The purpose of the research is to identify genetic variants that contribute to SSc disease susceptibility and influence outcome. The approach involves whole genome sequencing of 100 trios (300 individuals including affected case and both parents). Previous Genome-Wide-Association-Studies (GWAS) have identified gene regions that are associated with disease but the majority of these are in non-coding areas so the impact of these variants is unclear. This study will identify rare variants (both inherited and de novo mutations) and will analyze these mutations according to the role they likely plan in disease pathogenesis. The immediate outcome of this project will be identification of the causal variants in multiple pathways associated with SSc susceptibility with the long-range impact will be the identification of the role these variants plan in disease causation and severity/outcome. This study is on track for completion of the largest whole genome sequencing (WGS) project in scleroderma. The samples have been submitted for sequencing and quality control procedures have been done requiring the replacement of DNA from 2 individuals. Data are eagerly anticipate in this coming year along with analysis and genotype/phenotype correlations.

15. SUBJECT TERMS
Systemic Sclerosis, scleroderma, genetics, whole genome sequencing

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
U					USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	UU		19b. TELEPHONE NUMBER *(include area code)*
U UnUlassified	U Unclassified	U Unclassified	Unclassified		